Patents Assigned to SmithKline Beecham Corporation
-
Patent number: 8252234Abstract: An apparatus is provided for producing pharmaceutical and pharmaceutical-like product. The apparatus provides real-time monitoring of the pharmaceutical product and can provide real-time control. The apparatus monitors the dosage both before and after it has been added to a carrier substrate. The apparatus can provide monitoring of each pharmaceutical product that is processed.Type: GrantFiled: June 9, 2005Date of Patent: August 28, 2012Assignee: SmithKline Beecham CorporationInventors: Allan J. Clarke, David George Doughty, Frederick H. Fiesser, David S. Wagner
-
Patent number: 8122849Abstract: An apparatus and method are provided for producing pharmaceutical and pharmaceutical-like products. The apparatus and method provide real-time monitoring of the pharmaceutical product and can provide real-time control. The apparatus and method can monitor the dosage both before and after it has been added to a carrier substrate. The apparatus and method can provide monitoring of each pharmaceutical product that is processed.Type: GrantFiled: June 9, 2005Date of Patent: February 28, 2012Assignee: SmithKline Beecham CorporationInventors: Allan J. Clarke, David George Doughty, Frederick H Fiesser, David Tainsh, Dwight Walker, David Wagner
-
Publication number: 20120045774Abstract: The enzyme Lp-PLA2 in purified form, an isolated nucleic acid molecule encoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2 in therapy and a method of screening compounds to identify those compounds which inhibit the enzyme.Type: ApplicationFiled: August 11, 2011Publication date: February 23, 2012Applicant: Smithkline Beecham CorporationInventors: Colin Houston MacPhee, David Graham Tew
-
Patent number: 8101244Abstract: An apparatus and method are provided for producing a plurality of products or processing a plurality of samples via dispensing. The apparatus and method provide real-time monitoring of the products/samples and can provide real-time control. The apparatus and method can monitor the liquid both before and after it has been added to a carrier substrate. The apparatus and method can provide monitoring of each product/sample that is processed.Type: GrantFiled: June 9, 2005Date of Patent: January 24, 2012Assignee: SmithKline Beecham CorporationInventors: Allan J. Clarke, David George Doughty, Frederick H. Fiesser
-
Patent number: 8022032Abstract: The method set out herein involves identifying the concentration of each of two or more active therapeutics tailored to treat a particular patient's unique metabolism and one or more diseases, communicating that information to a producer who has multiple fixed or variable concentrations of each active available, where the producer then combines the individual concentrations of each active into single units such as a tablets or pills, and distributes those indirectly or directly to the patient.Type: GrantFiled: November 18, 2005Date of Patent: September 20, 2011Assignee: SmithKline Beecham CorporationInventors: Richard L. Kirsh, Steven D. Finkelmeier, Robert Glinecke, Luigi Martini
-
Publication number: 20110124559Abstract: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.Type: ApplicationFiled: August 8, 2007Publication date: May 26, 2011Applicant: Smithkline Beecham CorporationInventors: David John Cowan, Andrew Lamont Larkin, Cunyu Zhang, David Lee Musso, Gary Martin Green, Rodolfo Cadilla, Paul Kenneth Spearing, Michael Joseph Bishop, Jason Daniel Speake
-
Patent number: 7910321Abstract: The present invention relates to novel members of the Tumor Necrosis Factor family of receptors. The invention provides isolated nucleic acid molecules encoding a human TR2 receptor and two splice variants thereof. TR2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR2 receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of TR2 receptors. Further provided are therapeutic methods for treating disease states related to aberrant proliferation and differentiation of cells which express the TR2 receptors.Type: GrantFiled: September 23, 2008Date of Patent: March 22, 2011Assignees: Human Genome Sciences, Inc., SmithKline Beecham CorporationInventors: Jian Ni, Craig A. Rosen, Reiner L. Gentz, Sally Doreen P. Lyn, Mark Hurle
-
Patent number: 7858319Abstract: Methods of assessing the risk of clinical signs of hypersensitivity reaction to nucleoside antiviral compounds, including abacavir, are described. The methods include genotyping subjects for polymorphisms in the TNF? gene, the class 1 HLA genes, or a combination of both the TNF? and HLA genes.Type: GrantFiled: April 22, 2009Date of Patent: December 28, 2010Assignee: SmithKline Beecham CorporationInventors: Seth Hetherington, Arlene R Hughes, Eric H Lai, Michael Mosteller, Jr., Denise D Shortino
-
Publication number: 20100311775Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R3, R5, R6, R13, A, B, Y, Z, x, and m are defined herein, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.Type: ApplicationFiled: January 30, 2009Publication date: December 9, 2010Applicant: SmithKline Beecham CorporationInventors: Joseph Paul Marino, JR., John Jeffrey McAtee
-
Publication number: 20100273661Abstract: A method for predicting treatment response of a type II diabetes patient to rosiglitazone is provided. The method involves at least one sample from a patient having type II diabetes and analyzing biomarkers predictive of a patient who will respond to treatment with rosiglitazone. The biomarkers include, at least, interleukin-8, histidine, citrate. These biomarkers are identified in at least one classification analyses selected from the group consisting of a majority-vote based classifier and support-vector machine (SVM) classifier. Also provided is a method for predicting treatment response of a type II diabetes patient to glyburide at 8 weeks post-initiation of therapy. The method involves obtaining a sample from a type II diabetes patient who has been treated with glyburide for about 4 weeks and analyzing biomarkers predictive of a patient who will respond to treatment with glyburide at 8 weeks. The biomarkers useful in this method include, at least, sphingomyelin 23:1 and L-phenylalanine.Type: ApplicationFiled: June 11, 2008Publication date: October 28, 2010Applicants: SmithKline Beecham Corporation, BG Medicine IncInventors: Yang Qiu, Dilip Rajagopalan, Lei Zhu, Susan C Connor, Guanghui Hu, David Maclean, Doris Damian, Amir Handzel, Rajalakshmi Balasubramanian
-
Publication number: 20100272743Abstract: S epidermidis polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides and DNA (RNA) for the treatment of infection, particularly infections arising from S epidermidis. Antagonists against the function of such polypeptides and their use as therapeutics to treat infection are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to the presence of S epidermidis nucleic acid sequences and the polypeptides in a host.Type: ApplicationFiled: January 19, 2007Publication date: October 28, 2010Applicant: SmithKline Beecham CorporationInventor: William John Kimmerly
-
Patent number: 7812016Abstract: The present invention features compounds that are HIV integrase inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.Type: GrantFiled: May 12, 2004Date of Patent: October 12, 2010Assignee: SmithKline Beecham CorporationInventor: Brian A. Johns
-
Publication number: 20100160209Abstract: The invention provides for a cell permeable peptide conjugated to an insulin compound for improved cell penetration of the insulin moiety. The composition may be delivered by intravenous, intramuscular, subcutaneous, intranasal, oral inhalation, intrarectal, intravaginal or intraperitoneal means for the treatment, including prophylaxis of Type I, Type II diabetes, prediabetes and/or metabolic syndrome.Type: ApplicationFiled: May 10, 2007Publication date: June 24, 2010Applicant: SmithKline Beecham CorporationInventors: Dany Doucet, Mickey Lee Wells
-
Patent number: 7713982Abstract: The present invention relates to a therapeutically active xanthine derivative compound of formula (I): corresponding pharmaceutical formulations containing, manufacture processes for, methods or uses of such compounds in therapy, in particular for treatment of diseases where under-activation of the HM74A receptor contributes to such diseases or where activation of the HM74A receptor will be beneficial.Type: GrantFiled: February 10, 2005Date of Patent: May 11, 2010Assignee: Smithkline Beecham CorporationInventor: Ivan Leo Pinto
-
Publication number: 20100086547Abstract: The present invention relates generally to the methods for the treatment and diagnosis of conditions mediated by IL-5 and excess eosinophil production, and more specifically to mAbs, Fabs, chimeric and humanized antibodies. More particularly, methods are provided for reducing eosinophils in a human in need thereof, which method comprises administering to said human a composition comprising at least one anti-IL-5 antibody, wherein at least one anti-IL-5 antibody provides a mean maximum plasma concentration of said anti-IL-5 antibody of at least about 1.03±0.21 ?g/mL, an Area Under the Curve value of at least about 15.5±2.7 ?g/day/mL and a serum half-life of about 16.2±2.1 days to about 21.7±2.8 days.Type: ApplicationFiled: April 30, 2008Publication date: April 8, 2010Applicant: SmithKline Beecham CorporationInventors: Bela Rajiv Patel, Deborah Smith, Debra J. Tompson, Parnian Zia-Amirhosseini
-
Publication number: 20100086554Abstract: The present invention relates to methods of treating nasal polyposis, in a human, comprising the step of administering to said human in need thereof an effective amount of a composition comprising at least one anti-11-5 antibody wherein said antibody comprises a heavy chain and a light chain.Type: ApplicationFiled: April 30, 2008Publication date: April 8, 2010Applicant: SmithKline Beecham CorporationInventor: Claus Bachert
-
Publication number: 20100081792Abstract: The invention provides a dual-specific ligand comprising a first and second single variable domain, each having binding specificity for a antigenic target. The invention also provides for a single variable domain monomer ligand that specifically binds to an antigenic target.Type: ApplicationFiled: October 31, 2007Publication date: April 1, 2010Applicant: SmithKline Beecham CorporationInventors: Steven Grant, Amrik Basran, Olga Ignatovich, Rudolph Maria T. De Wildt, Philip Jones, Neil Brewis, Ben Woolven, Elena De Angelis, Lucy J. Holt, Greg Winter, Ian Tomlinson, Kevin Moulder
-
Publication number: 20100056760Abstract: Monoclonal antibodies have been generated that bind to human sialoadhesion factor-2. These antibodies are useful as diagnostic and therapeutic reagents.Type: ApplicationFiled: May 29, 2009Publication date: March 4, 2010Applicant: SmithKline Beecham CorporationInventors: Julie A. ABRAHAMSON, Connie L. Erickson-Miller, Kristine K. Kikly, Bruce Bochner, Robert Schleimer, T. Esra Nutku
-
Patent number: 7668662Abstract: A patient-specific optimally effective radiation dose for administration of a radiopharmaceutical to a patient for treatment of a disease may be established by basing the calculation of the appropriate therapeutic dose on factors such as the desired total body dose, the maximum tolerated dose, the typical clearance profile of the radiopharmaceutical, the patient's mass or maximum effective mass, and the patient-specific residence time of the radiopharmaceutical or an analog in the whole body of the patient. The use of the method allows for treatment of a patient with an appropriate dose which is maximally effective against the disease yet minimally toxic. The determination of a patient-specific therapeutic dose may be assisted by the use of a software program set to the particular parameters of the radiopharmaceutical.Type: GrantFiled: August 10, 2005Date of Patent: February 23, 2010Assignees: The Regents of the University of Michigan, Smithkline Beecham CorporationInventors: Stewart M. Kroll, Jeffry A. Siegal, Richard L. Wahl, Kenneth R. Zasadny
-
Patent number: D662203Type: GrantFiled: June 20, 2011Date of Patent: June 19, 2012Assignee: SmithKline Beecham CorporationInventor: David William Smith